FTC wins $448 million disgorgement from AbbVie and Besins

AbbVie has said it will appeal its loss against the Federal Trade Commission in a lawsuit for monopolising Androgel through sham litigation, as a Pennsylvania federal court ordered the drugmaker and Besins Healthcare to pay $448 million to consumers.

Get unlimited access to all Global Competition Review content